China (Mainland)
High Quality Simendan CAS NO.131741-08-7
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
1(1-2)Gram
- Product Details
Keywords
- 131741-08-7
- Simendan
- Simendan Price
Quick Details
- ProName: High Quality Simendan
- CasNo: 131741-08-7
- Molecular Formula: C14H12N6O
- Appearance: White powder
- Application: pharmaceutical intermediates
- DeliveryTime: Qingdao Port
- PackAge: 1kg or 25Kg drum
- Port: QIngdao Port
- ProductionCapacity: 3000 Metric Ton/Year
- Purity: 98% HPLC
- Storage: Store in dry, dark and ventilated plac...
- Transportation: By air or by sea. Prompt delivery
- LimitNum: 1 Gram
- Moisture Content: See data sheet
- Samples: Available
Superiority
Qingdao Sigma Chemical Ltd is is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates, peptide,Nootropis etc API, food and feed additives, herbal extracts, agrochemicals and fine chemicals etc.
Our Laboratory is located in shandong province. There are 15 experts in our research team. Talented personnel and well-equipped laboratory makes rigorous and professional quality control possible. Lyphar Biotech is equipped with various detection devices, such as HPLC, GC, Spectrophotometer, AAS, Polarimeter, Auto titrators, BOD Incubators, COD Incubators, Melting point apparatus and so on.
The aim of QDSIGMA is a quality policy that "Elements in the system all have been satisfied, Personnel has been trained; Every batch of material is checked, Each procedure guarantees the quality; Every bag of our products is top grade, Service is thoughtful all the time, quality and reputation to increase market share and promote enterprise development. The quality, colors and forms of our products have reached a high level in related chemical industry, which relies on characteristic and advanced processing technology and it has gained a high and reliable reputation from customers at both quality and services.
QDSIGMA has become the "Top 500 Chinese manufacturing companies","Top 20 of global chemical sales".QDSIGMA has 21 subsidiaries and holding companies.
We promise our customer following items
1.Reasonable price:
2.Low moq:No worry about the low moq, our moq is 1 gram or lower.
3.Good and efficient service,Fast Delivery
4.Super-good quality
Details
pharmaceutical powder levosimendan for anti-heart failure
quick detail
|
product name
|
levosimendan |
|
synonym
|
simendan;(r)-simendan;simda;mesoxalonitrile
(-)-{p-[(r)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl}hydrazone
|
|
cas no
|
131741-08-7
|
|
mf
|
c14h12n6o
|
|
mw
|
280.28
|
| appearance |
white powder
|
|
purity
|
99%
|
| melting point |
216-219°c (dec.)
|
| solubility |
dmso:≥20mg/ml |
|
grade
|
pharma grade
|
| usage |
levosimendan is a ca2+ sensitizer that increases
contractile force of the myocardium by enhancing the
sensitivity of myofilaments to calcium without increasing intracellular calcium concentration.
|
description
levosimendan is a calcium sensitiser it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin c in a calcium-dependent manner. it also has a vasodilatory effect, by opening adenosine triphosphate (atp)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation.the combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload. moreover, by opening also the mitochondrial (atp)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.
mechanism
levosimendan does not directly increase the intracellular calcium concentration or increase the troponin affinity with ca2+, but binds to the amino terminal amino acid of troponin c (tnc) on the myocardial myofilament, increasing the tnc conformational stability with ca2 + complexes. after tnc and ca2 + binding, the molecular conformation of the original myosin changes, which lifted its impeding effect on the binding of myofibrillar and cross bridges. cross-bridge with thin filaments, myofibril twist, myocardial fiber contraction. in addition levosimendan and tnc binding was ca2 + concentration-dependent, that is, when the intracellular ca2 + concentration is high (myocardial cell contraction), it has high affinity with tnc, and intracellular ca2 + concentration is low (myocardial when cells relax), it has low affinity for tnc. so it has the strongest systolic and diastolic effects, thus preventing or alleviating possible diastolic dysfunction.
inflammatory cytokines, oxidative stress and cardiomyocyte apoptosis play an important role in myocardial remodeling, and myocardial remodeling is the basic pathophysiological basis leading to the continuous progress of heart failure.levosimendan can reduce the levels of il-6, tnf-α, mda, bnp in heart failure patients, and reduce the level of soluble fas signaling molecules fas / fas ligand, which has anti-inflammatory, anti-oxidation and anti-apoptosis in cardiomyocytes.
in addition to calcium sensitization to cardiac myofilaments,levosimendan can also inhibit cardiac
phosphodiesterase (mainly phosphodiesterase iii) activity in the same way as phosphodiesterase inhibitors: camp degradation blocked, camp increased, and further increase the activity of protein kinase on the cell membrane, and then act on camp-mediated information transfer, the content of intracellular camp increased, calcium channel membrane protein phosphorylation, increased ca2 influx, myocardial shrink has been strengthened.
in vitro, levosimendan was found to selectively inhibit type iii phosphodiesterase activity, but this effect is evident only when the recommended dose is exceeded. therefore, its positive inotropic effect at a clinical dose has nothing to do with its inhibitory effect on phosphodiesterase.
